Codagenix
Ms. Tea has experience in clinical trials with cross functional knowledge in trial management, data management, and compliance for domestic and multi-center global clinical trials. Her experience spans all stages of clinical development, from Phase I to Phase III trials. She has prior clinical research experience in academic research centers and biotechnology firms across multiple therapeutic areas and functions. Prior to joining Codagenix, she played an integral part in bringing a novel Peripheral Artery Disease combination device to research centers. Lasmy earned an MPH in Global Public Health from New York University and an MS in Information Management from Columbia University.
This person is not in any offices
Codagenix
Codagenix Inc. is a clinical stage biotechnology company with vaccine products against influenza, respiratory syncytial virus, dengue virus, and others currently under development.